Reasons for Discontinuation2
In a Breast Cancer Index® decision impact study led by Yale and UPMC, after receiving their results, 82% of patients that were recommended extended endocrine therapy reported they were more likely to be compliant with their treatment plan.10
References: 1. Goss PE et al. N Engl J Med. 2016 Jul 21;375(3):209-19. 2. Mamounas et al. Lancet Oncol 2019; 20: 88-99. 3. Hershman et al. Breast Cancer Res Treat. 2011; 126(2): 529-537. 4. Partridge, A. H. et al. J Clin Oncol; 21:602-606 2003. 5. Murphy CC, et al Breast Can Res Treat. 2012;134:459-4. 6. Sheppard VB et al. J Clin Oncol. 2014 Aug 1;32(22):2318-27. 7. Davies C et al., Lancet. 2013 ;381(9869):805-16. 8. Goss PE et al., N Engl J Med. 2003;349. 9. Goss PE et al. JNCI 2005; 97(17): 1262-71. 10. Sanft et al. Breast Cancer Manag 2019;8(1).
Back To All